ABSTRACT BACKGROUND There are several options available for aortic valve replacement (AVR), with few comparative reports in
Each has its uses and limitations and, more importantly, no option is perfect. There is a set of qualities an AoV substitute should have, and presently there is no choice that can achieve them all, with many factors influencing the choice and long-term results of an AVR. Data on outcomes vary, with few national and even fewer comparative studies. Multicenter studies would be best suited to describe and compare modern results. The objective of the current study is to describe early and long-term survival and freedom from reintervention in a national population of consecutive, unselected young patients, to compare the results of the main types of AVR in appropriately matched populations and to identify factors influencing outcome for each procedure type.
METHODS
The National Congenital Heart Disease Audit collects validated key data on cardiac procedures from all the UK units, using a mechanism for data capture, We excluded 671 patients who were >40 years of age, as we considered that above this age degenerative disease is more prevalent.
We also excluded those patients with associated complex heart abnormalities (n ¼ 193), rheumatic fever (n ¼ 15), unclassified AVR procedures (n ¼ 313), and unknown age at index procedure (n ¼ 74). The excluded complex heart abnormalities were univentricular conditions, valvar atresias, interrupted aortic arch, atrioventricular septal defect, transposition of great arteries, common arterial trunk, Fallot-type defects, severe vascular abnormalities (e.g., major aortopulmonary collaterals), and atrial isomerism. Unclassified AVR procedures were due to errors in reporting (i.e., using a general "Aortic valve replacement" code).
Reinterventions were defined as either reoperations or catheter-based procedures related to the AoV or root and to the pulmonary valve and right ventricle outflow tract (RVOT) for the Ross operation group. Not included were early reinterventions (within 30 days, considered connected to intraoperative events and not prosthesis durability) and those aorta dilation/aneurysm repairs that were related to previous conditions (e.g., Marfan syndrome). When comparing the procedures, separate calculations were made for AoV reinterventions and any reinterventions, due to the fact that the Ross procedure is at risk of both AoV and RVOT reinterventions. This was done to ensure that the comparisons between procedures can be properly interpreted, with both AoV and overall freedom from reintervention comparisons. 
RESULTS
A total of 1,501 patients <40 years of age who underwent an AVR procedure were included in the analysis. Of these, 718 (47.8%) had R-AVR, 567 (37.8%) had M-AVR, 163 (10.9%) had B-AVR, and 53 (3.5%) had H-AVR. There were significant differences in age and sex between groups, most notably R-AVR patients being younger than in the other 3 groups (R-AVR mean 13. The short-and long-term outcome estimates are shown in Table 3 . The best results were achieved in the R-AVR group, with 97.3% survival and 94.7% The columns represent fraction from total for 1-year-wide bins. The continuous line represents the kernel density. Coarctation/hypoplasia repair
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neonates and infants compared to children and young adults, especially within the early phase of the first 3 years of follow-up ( Figure 7A ). AoV regurgitation is associated with higher reintervention risk, compared to mixed disease and stenosis ( Figure 7B ). The risk becomes statistically significant shortly after surgery but does not exhibit a dynamic behavior. Age appears to have a steady impact on pulmonary reintervention: the younger the patient, the higher the risk ( Figure 7C ). The HRs are steady and statistically significant over time. This is in contrast to the earlyphase impact of age on mortality risk ( Figure 7A ).
Time independence of age HR for pulmonary reintervention suggests that the increased risk with younger age is related to the procedure performed and is not influenced by time-varying factors. We did not find sex to be a predictor of pulmonary reintervention or death.
M e c h a n i c a l p r o s t h e s i s . No predictors for mortality were found in this group. Younger age was associated with significantly higher hazard and cumulative incidence for aortic reintervention ( Figure 7D) . Hazard functions are derived from multivariable Bayesian mixture survival models (separate for Ross and mechanical aortic valve replacement
[AVR]), using the additive mixture of 2 Weibull hazards, adjusted by age (continuous), age group, sex, aortic disease type, mitral disease, coarctation, subaortic stenosis, genetic syndrome, mitral valve procedure, coarctation repair, and subaortic stenosis repair at index. The midpoint of each age group was chosen as the age of its corresponding hypothetical patient, whereas the rest of the categorical variables were set as zero. (A) Impact of age on mortality risk for Ross procedure. (B) Impact of aortic disease type on reintervention risk for Ross procedure.
(C) Impact of age on risk of pulmonary reintervention for Ross procedure. (D) Impact of age on reintervention risk for the mechanical AVR procedure in young adults. Dynamic hazard ratios, CI differences, event-free probability differences, and their corresponding p values can be seen in the Online Appendix.
Sharabiani et al. grounds that palliation can achieve good results (11, 12) , whereas AVR mortality in these patients is high, ranging from 15% to 50% (12) (13) (14) . We have seen a lower early mortality in this age group (10%) but still we found that age under 1 year is a risk factor in the R-AVR overall. The lower mortality may be related to excluding patients with complex associated defects, like interrupted arch, specifically found to be a risk factor by others (6, 15) . Hickey et al. (10) report high mortality in neonates and infants undergoing a Ross procedure, but these patients had either critical stenosis or a failed previous repair, the results being otherwise acceptable for patients older than 3 months presenting electively. In other words performing a Ross procedure in unfavorable circumstances may lead to unfavorable results, but these are situations where alternatives are limited.
We found that <1 year of age was a significant risk factor for pulmonary conduit reintervention, as pre- (Figure 3) . These results persist in pairwise comparisons, which broaden the matched groups depending on the particular overlap in age (Figures 4 to 6 ).
Comparing the Ross procedure and mechanical AVR we found a slightly higher mortality and aortic reintervention risk in M-AVR, but overall event-free probabilities are comparable after considering the RVOT reinterventions (Figure 4) . Mokhles et al. (21) compared the R-AVR and optimally anticoagulated M-AVR in propensity score matched groups for the nonelderly adult population, finding no differences in mortality and significantly higher aortic reintervention rates in the Ross group. There are several differences between this study and ours: our patients are younger, we did not use propensity matching but rather a composite approach, and finally our M-AVR patients were not under highly specialized anticoagulation but under real-life conditions when compliance is variable.
Few reports compare the Ross procedure with the bioprosthetic valve in the young. Ruzmetov et al. (22) reported better survival with Ross at 15 years (91% vs. 84%) (but children were also included and noted to have higher mortality), comparable freedom from aortic reintervention, and higher risk of AoV explantation in the bioprosthesis group. We found no differences in long-term mortality in our matched groups (the difference being we compared only young adults), but we did find a higher risk for AoV reintervention in the B-AVR group, especially starting after 2 years of follow-up ( Figure 5 ).
Comparing the mechanical to bioprosthetic valves in matched young adults groups, we found modest differences in mortality and aortic reintervention, the risks being slightly higher in the latter ( Figure 6 ). RISK FACTORS ASSOCIATED WITH AVR. Our data originated in a procedure-based audit, and therefore we had few other variables to consider as predictors.
The focus became age, valve disease type, and concomitant defects and procedures, also looking into the dynamic effect they might have during follow-up. The choice to apply dynamic survival analysis was influenced by the belief that some key drivers of outcome may not have the same impact in various stages of follow-up. Our results highlighted 3 cases of age influencing outcome: mortality risk and pulmonary reintervention for the Ross procedure, and aortic reintervention for M-AVR (Figure 7) . In the first case, we saw a strong early-phase hazard for neonates and infants compared to children and young adults, consistent with the more severe clinical condition associated with presentation at earlier ages. In the other 2 cases, an increased hazard for younger patients was noted which lasted long into follow-up. This is consistent with an inherently higher risk due to the initial surgery. A dynamic model allowed us to differentiate these 2 patterns and hypothesize about the different root-causes of each. Of course an alternative is to build independent models for different age groups to allow for arbitrary HRs between them, but this would not be as efficient a use of data as building a single model that contains all age groups. 
